Jaume Capdevila

Jaume Capdevila

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 203 publications

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Journal: BMC cancer

Published: June 13, 2026

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 07, 2026

Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohort.

Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohort.

Journal: The oncologist

Published: February 27, 2026

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.

Journal: The oncologist

Published: February 27, 2026

OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer.

OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer.

Journal: Communications medicine

Published: February 23, 2026

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 20, 2026

Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.

Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.

Journal: Frontiers in oncology

Published: February 02, 2026

Proximal-To-Distal Gradient and Its Implications in Differentiation and Prognosis in Colorectal Neuroendocrine Neoplasms: The RGETNE-HERACLES Study.

Proximal-To-Distal Gradient and Its Implications in Differentiation and Prognosis in Colorectal Neuroendocrine Neoplasms: The RGETNE-HERACLES Study.

Journal: Neuroendocrinology

Published: January 21, 2026

Inferior Vena Cava Stenosis Mimicking Right Heart Failure in Carcinoid Heart Disease.

Inferior Vena Cava Stenosis Mimicking Right Heart Failure in Carcinoid Heart Disease.

Journal: JACC. Case reports

Published: January 19, 2026

A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic neuroendocrine neoplasms: results from NUTRIGETNE (GETNE-S2109) study.

A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic neuroendocrine neoplasms: results from NUTRIGETNE (GETNE-S2109) study.

Journal: Frontiers in nutrition

Published: January 19, 2026

European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids.

European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids.

Journal: Journal of neuroendocrinology

Published: January 09, 2026

[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial.

[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial.

Journal: EClinicalMedicine

Published: January 07, 2026

Showing 1-12 of 203

Last Updated: 09/26/2026